Journal Article

Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma

Karmisholt, Jesper Scott, Vestergaard, Peter, Ettrup, Kåre Schmidt, Dal, Jakob, Gjersdal, Erlend, Nielsen, Eigil Husted, Müller, Hermann L., Larsen, Liva Bundgaard

2024

Overview

Purpose Patients with hypothalamic pathology often develop hypothalamic obesity, causing severe metabolic alterations resulting in increased morbidity and mortality. Treatments for hypothalamic obesity have not proven very effective, although the glucagon-like peptide-1 receptor agonist semaglutide has been shown to have positive effects. We examined semaglutide’s effect on weight loss in a sample of patients with hypothalamic obesity. Methods Four female patients with hypothalamic obesity resulting from treatment of craniopharyngiomas were treated with semaglutide for six months. Whole Body Dual-energy x-ray absorptiometry scans were performed, and blood samples drawn at baseline and after six months. Semaglutide dosages were increased monthly along with tracking of body weight and eating behavior (Three Factor Eating Questionnaire, TFEQ-R18). Results BMI was reduced in all cases, with an average of 7.9 BMI (range: 6.7 to 10.1) corresponding to a weight loss of 17.0% (range: 11.3–22.4%) or 20.2 kg (range 16.2 kg to 23.4 kg). We found a comparable reduction in total fat mass (17.2%, p  = 0.006) and lean mass (16.0%, p  = 0.05), whereas bone mass was unchanged (2.6%, p  = 0.12). All cases reported an increase in energy levels, improved mobility and physical activity. Unfavorable eating behaviors were reduced after 1 month of treatment (emotional eating − 41 points, p  = 0.02, uncontrolled eating − 23 points, p  = 0.11). HbA1c and total cholesterol were significantly reduced ( p  = 0.014 for both). Conclusion Semaglutide is a promising and safe treatment option for HO, that improves eating behavior, reduces weight, and improves metabolic markers.

• Publisher: Springer US,Springer Nature B.V
• Subject: Absorptiometry, Photon / Antidiabetics / Body fat / Body Mass Index / Body weight loss / Bone mass / Cholesterol / Craniopharyngioma - drug therapy / Dual energy X-ray absorptiometry / Eating behavior / Emotional behavior / Endocrinology / Female / GLP-1 receptor agonists / Glucagon / Glucagon-like peptide 1 / Glucagon-Like Peptides - therapeutic use / Human Physiology / Humans / Hypothalamus / Medicine / Medicine & Public Health / Metabolism / Morbidity / Neoplasia / Obesity / Obesity - drug therapy / Physical activity / Pituitary / Pituitary Neoplasms - drug therapy / Weight control